Working around the notion that cancer-causing mutations on receptors found in bone marrow stem cells could explain why some patients grow resistant to currently used leukemia drugs, researchers at the Indiana University School of Medicine say they've been successful in testing a new approach to fighting the disease.
Myriad Genetics said results from a study of its myPath Melanoma test showed a 43% reduction in indeterminate diagnoses of skin cancer and nearly a 50% change by doctors in their treatment recommendations for patients.
Diagnostics luminary Foundation Medicine is generating some upward momentum, fueled by growing revenues and the success of its clinical tests. Tech giant Google has taken note and is signing onto the company's cancer diagnostics by offering them to employees.
Cleveland Clinic scientists believe they have identified possible blood biomarkers that could help detect lung cancer, based on the alteration of metabolic processes that happens to patients with the disease at various stages.
A subsidiary of French in vitro diagnostics giant bioMérieux gained Medicare coverage for a new breast cancer test, a vital milestone necessary to compete in today's market.
Sequenta attracted new equity investment from Celgene and other unnamed parties that back the use of its technology in the drug development process and the creation of new ultraprecise diagnostic tests.
Biocept forged a partnership deal with a competitor that aims to build an enhanced molecular diagnostics test for circulating tumor cells in the blood. Success could breed a more precise test that aids patient diagnoses and drug development in equal measure.
Merck Serono is teaming up with London's Institute of Cancer Research and the charitable Wellcome Trust to identify and develop new inhibitors to treat cancer.
In an effort to better understand a certain disease-causing enzyme, British researchers have created a "map" of more than 100 proteins this enzyme is known to affect. They then identified a druglike molecule that blocks this enzyme to preserve these essential proteins.
In late 2014, the push to develop universal companion diagnostics to facilitate personal treatments for multiple cancers appears to be accelerating.